1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

iPierian raises $30m to target tau, spin out complement program

 
• By Mandy Jackson

South San Francisco-based iPierian raised $30m in private financing to prepare its monoclonal antibody targeting the tau protein for clinical development and to fund a series A round for the new company True North Therapeutics, which will develop iPierian's monoclonal antibody that selectively inhibits the classical complement pathway for the treatment of rare diseases.

South San Francisco-based iPierian raised $30m in private financing to prepare its monoclonal antibody targeting the tau protein for clinical development and to fund a series A round for the new company True North Therapeutics, which will develop iPierian's monoclonal antibody that selectively inhibits the classical complement pathway for the treatment of rare diseases.

IPierian CEO Nancy Stagliano said 16 months ago that the company would focus on the development of monoclonal antibodies targeting tau and the complement pathway for neurodegenerative diseases (scripintelligence.com,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.